NCT01061814View on ClinicalTrials.gov

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

June 30, 2010

Conditions
Healthy Volunteer
Interventions
DRUG

mipomersen

30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks

DRUG

Placebo

30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks

Trial Locations (1)

H3X 2H9

Anapharm, Inc., Montreal

Sponsors
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Kastle Therapeutics, LLC

INDUSTRY

NCT01061814 - A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers | Biotech Hunter | Biotech Hunter